Description

Global Medical Affairs leader with 10+ years of experience driving regional medical strategy, pre-launch excellence, and scientific engagement across EMEA and emerging markets. Strong track record in alliance products, KOL strategy, team leadership, and delivery of high-impact medical programs aligned with business and patient outcomes.

Industry field of expertise

Languages

English
Native or bilingual
Spanish
Conversational
Portuguese
Native or bilingual
Italian
Conversational
German
Basic

Workplace preferences

Can work on-site

Zurich (up to 50km)

Johnson&Johnson Innovative Medicine
EMEA Scientific Knowledge Lead - Cardiopulmonary
PHARMACEUTICALS INDUSTRY
October 2024 - November 2025 (1 year and 1 month)
Zürich, Switzerland
12-month fixed-term contract (maternity leave cover)

Strategic Medical Affairs leader and regionally recognized scientific expert in cardiopulmonary diseases, providing scientific direction across Global, EMEA, and local Medical Affairs teams, supporting 30+ countries.

- Led and co-developed EMEA Medical Affairs strategies and tactical plans across cardiopulmonary indications (PAH, AF, ACS, SSP) covering pre-launch, in-market, and end-of-lifecycle phases.
- Co-responsible for the pre-launch medical strategy of an alliance product, shaping scientific positioning, core medical narratives, and cross-company alignment.
- Acted as a strategic scientific advisor to cross-functional stakeholders (Medical, Commercial, Market Access), ensuring alignment with business priorities and compliance standards.
- Directed regional medical education initiatives, international congress strategy, and EMEA-wide field force training, strengthening scientific excellence and consistent execution.
- Served as the primary regional interface for local Medical Affairs teams, aligning medical strategy and narratives across affiliates.
- Oversaw regional publication strategy, supporting and reviewing 5 publication concepts to ensure scientific rigor and strategic relevance.
- Designed and deployed centralized medical campaigns and field materials to enable effective, compliant HCP engagement across EMEA.

Achievements:
- Planned and executed EMEA presence at ESC and ERS 2025, including medical booths and symposia, reaching 10,000+ HCPs.
- Optimized Medical Affairs resources for end-of-lifecycle products by transitioning to digital-first strategies, improving reach and cost efficiency.
- Contributed with narrative development for a global product pre-launch.
Medical Education Strategic Alliance Medical Affairs Strategy KOL Engagement Congress Planning
AstraZeneca
International Severe Asthma Lead - OCS Stewardship
PHARMACEUTICALS INDUSTRY
February 2024 - July 2024 (5 months)
Temasek, Singapore
Selected for a high-potential talent development program (Plan 100) to lead the strategy and execution of Oral Corticosteroid Stewardship initiatives across 20+ international markets (LATAM, Middle East, Eurasia).

- Drove the design, adaptation, and deployment of international OCS stewardship resources, supporting optimal, evidence-based corticosteroid use across diverse healthcare systems.
- Reviewed and evaluated local market OCS stewardship activities, gathering structured feedback to refine global resources and improve uptake and impact.
- Supported data generation and publication activities, contributing to the scientific evidence base underpinning OCS stewardship strategies.
- Acted as a regional Medical Affairs interface, strengthening alignment between global strategy and local execution.
Strategic Influence Medical Affairs Strategy Data Generation Medical Programme Screening and Diagnosis
AstraZeneca
Medical Advisor Respiratory & Immunology (Severe Asthma Biologics)
PHARMACEUTICALS INDUSTRY
November 2022 - July 2024 (1 year and 8 months)
Temasek, Singapore
- Led the development and execution of Medical Affairs strategies aligned with business objectives, ensuring scientific integrity and patient-centric impact.
- Acted as a trusted scientific expert, delivering accurate, up-to-date medical insights to internal teams and external stakeholders.
- Led the pre-launch Medical Affairs strategy for an alliance product, shaping scientific positioning, core medical narratives, and cross-company alignment.
- Established and strengthened KOL and societies partnerships, enabling high-value scientific exchange, insight generation, and research collaboration.
- Served as Nominated Signatory (backup), supporting Oncology and CVRM business units.

Achievements:
- Recipient of the 2024 Best Team of Quarter for the successful launch of tezepelumab in Singapore.
- Achieved 92% conversion of KOLs to highest advocacy levels six months pre-launch, contributing to 3.8% market share in the first quarter post-launch (vs 2% for the main competitor in its first launch quarter).
Biologics KOL Advocacy Screening and Diagnosis Medical Affairs Strategy Pre-Launch